This trial is active, not recruiting.

Condition chronic migraine, headaches
Treatment onabotulinumtoxina
Sponsor Allergan
Start date November 2012
End date June 2014
Trial size 33 participants
Trial identifier NCT01749410, GMA-BTX-CM-12-491


This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine Headache patients who have received a minimum of 7 treatment cycles.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective
Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
onabotulinumtoxina botulinum toxin Type A
Previous treatment with onabotulinumtoxinA for Chronic Migraine.

Primary Outcomes

Number of Headache Days
time frame: Up to 2 years

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - 15 or more headache days over a 30 day period - A minimum of 7 treatment cycles with onabotulinumtoxinA Exclusion Criteria: - Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

Trial information was received from ClinicalTrials.gov and was last updated in April 2014.
Information provided to ClinicalTrials.gov by Allergan.